Carregant...
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome, resulting in the accumulation of proteasome substrates and ultimately growth arrest and apoptosis of tumor cells. The development and ultimate...
Guardat en:
| Publicat a: | Onco Targets Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5317297/ https://ncbi.nlm.nih.gov/pubmed/28243125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102756 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|